National Research Ethics Committee

NREC-CT A Meeting

22nd November 2023

Attendance

Name	Role
Prof. Alistair Nichol	Chairperson, NREC-CT A
Dr Heike Felzmann	Deputy Chairperson, NREC-CT A
Prof. Mary Donnelly	Deputy Chairperson, NREC-CT A
Dr Dervla Kelly	Committee Member, NREC-CT A
Dr Jimmy Devins	Committee Member, NREC-CT A
Prof. Catherine Hayes	Committee Member, NREC-CT A
Ms Muireann O'Briain	Committee Member, NREC-CT A
Prof. David Brayden	Committee Member, NREC-CT A
Prof. Patrick Dillon	Committee Member, NREC-CT A
Dr John O'Loughlin	Committee Member, NREC-CT A
Dr Darren Dahly	Committee Member, NREC-CT A
Prof. Gene Dempsey	Committee Member, NREC-CT A
Prof. Donal Brennan	Committee Member, NREC-CT A
Prof. Austin Duffy	Committee Member, NREC-CT A
Dr Geraldine Foley	Committee Member, NREC-CT A
Dr John O'Loughlin	Committee Member, NREC-CT A
Ms Ann Twomey	Committee Member, NREC-CT A
Dr Katherine Benson	Committee Member, NREC-CT A
Ms Susan Finnerty	Committee Member, NREC-CT A
Dr Dawn Swan	Committee Member, NREC-CT A

Ms Dympna Devenney	Committee Member, NREC-CT A
Dr Andrew Lindsay	Committee Member, NREC-CT A
Dr Meave Kelleher	Committee Member, NREC-CT A
Prof Fionnuala Breathnach	Committee Member, NREC-CT A
Ms Patricia Kenny*	Project Officer, National Office for RECs
Dr Laura Mackey	Programme Officer, National Office for RECs
Dr Susan Quinn	Programme Officer, National Office for RECs

Apologies: Prof John Wells, Mr Gerard Daly, Ms Evelyn O'Shea, Mr Gerard Eastwood, Mrs Erica Bennett, Tina Hickey, Prof Andrew Smyth, Dr Sean Lacey

Quorum for decisions: Yes

Agenda

- Welcome & Apologies
- 2023-505543-39-00
- 2022-502785-25-00
- 2023-504923-20-00
- 2023-507881-19-00
- 23-NREC-CT-039_Mod-2
- 22-NREC-CT-170_Mod-1
- AOB

- The Chair welcomed the NREC-CT A.
  - The minutes from the previous NREC-CT A meeting on 25th October 2023 were approved.
  - The NREC Business Report was discussed and noted.

Applications

2023-505543-39-00

Principal Investigators & Institutions: Tallaght University Hospital (Dr Patrick Mitchell), Cork University Hospital (Prof. Desmond Murphy), University Hospital Galway (Dr Ruth Cusack)

Study title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallelgroup, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA)

EudraCT: 2023-505543-39-00

- **NREC-CT comments:**
- The NREC-CT A agreed that additional information was required to inform its deliberations before a final ethics position could be returned. RFI

- **NREC-CT Decision:**
- Request for more information

Part I Considerations (RFI) for addition to CTIS

1. No Considerations raised
-

Part II Considerations (RFI) for addition to CTIS

1. **Compliance with use of biological samples**

- It was unclear to the NREC-CT why the biosamples directly relevant to the trial are not pseudoanonymised. Please clarify.
- It was unclear to the NREC-CT why samples for future research will be pseudonymized rather than anonymized when participants are not going to be recontacted regarding the future use of these samples. The Committee would request that the samples for future use be anonymized, or justification provided for keeping them pseudonymized. If samples for future use are to be anonymized, please update the relevant PISCF/s to included specific consent to anonymise the data.
- The NREC-CT noted the response to Q4.8 of Compliance the collection, use and storage of biological samples regarding requests for secondary future use of samples. The Committee requested that this be updated to include reference to ethical approval also being sought for any future research studies.

2. **Recruitment arrangements**

- The NREC-CT noted that Section 1.2 of the Recruitment Arrangements only refers to the PISCF. The Committee requested clarification if there will be additional recruitment materials to be used such as brochures, posters etc, if so please supply these for review.

3. **Subject information and informed consent form**

- It was not clear to the NREC-CT from the study documentation how participants will claim reimbursements. The Committee requests that the SIS and ICF Adult Subject be updated to provide information for participants on how they can claim reimbursements.
- The NREC-CT notes that pg 5 of the SIS and ICF Adult Subject mentions caregiver. The NREC-CT requested confirmation that caregivers will be reimbursed for out-of-pocket expenses should they accompany the participant to study visits. The Committee also requested the PISCF be updated to clarify this.

4. **Suitability of the clinical trial sites facilities**

- The NREC-CT requests that further information on Dr Mitchell's previous clinical trial experience is added to the CV template.

2022-502785-25-00

Principal Investigators & Institutions: Beaumont Hospital (Dr Philip Murphy), St James's Hospital (Dr Robert Henderson)

Study title: A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 x anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

EudraCT: 2022-502785-25-00

- **NREC-CT comments:**
- The NREC-CT A agreed that additional information was required to inform its deliberations before a final ethics position could be returned. RFI

- **NREC-CT Decision:**
- Request for more information

Part I Considerations (RFI) for addition to CTIS

1. No considerations raised
-

Part II Considerations (RFI) for addition to CTIS

1. Recruitment arrangements

- The NREC-CT noted that Section 1.1 of the Recruitment and ICF Process refers to “letters, posters, flyers, and advertisements in print or on the trial site’s website” being used to recruit participants, however these were not submitted for review. The Committee requested that any recruitment materials be supplied for review.

2. Subject information and informed consent form

- The NREC-CT notes that on page 5 of the Main SIS-ICF, participants who live within 20 minutes of the treating facility may be discharged as part of the CSR monitoring process. This discharge is not considered appropriate for Irish participants and the committee requests that this is removed from the participant materials. It is requested that participants should be hospitalised during the period of close monitoring as outlined in the participant information leaflet. This will be considered a condition of approval in Ireland. The sponsor should confirm that investigators in Ireland will be made aware of this requirement.
- The NREC-CT notes that the SIS-ICF Main pg 6 details tests and procedures scheduled. The Committee requests that the SIS-ICF Main be updated to include a table showing the schedule of these tests and procedures in order to ensure the participant is informed.
- The NREC-CT requests that the SIS-ICF Main pg 17 be updated to provide further detail on “effective method of contraception”, The Committee also requests confirmation that the person who will be performing the consent process will be suitably qualified to have a discussion regarding contraception advice.
- The NREC-CT requests that the Main SIS-ICF pg 20, be updated to include reference to the separate additional consent forms in ‘How will my personal data be used’ section.
- The NREC-CT requests that Pregnant Partner SIS-ICF pg 2 ‘What kind of information will be collected?’ section be updated to define the period of follow up for collection of information about the health of the child after birth.
- The NREC-CT requests that the Pregnant Partner SIS-ICF pg 5 be updated to include a sentence outlining the consent for processing of data such as “I agree for my health data to be processed and shared as described in this information sheet in accordance with the current Data Protection Legislation” or similar.
- The NREC-CT requests that the Pregnant Partner SIS-ICF pg 5 be updated to include a sentence outlining the consent for collection of the baby’s data such as “I agree for the collection of information about health of my baby to

be processed and shared as described in this information sheet in accordance with the current Data Protection Legislation" or similar.

- The NREC-CT notes that if the pregnant partner does not wish to be contacted directly they can give permission for their personal doctor to release the information to the study doctor,. The Committee requests that the Pregnant Partner SIS-ICF pg 5 be updated to include the option for the participant to consent, to their GP/personal doctor releasing the information on their pregnancy.
- The NREC-CT requests that the Pharmacogenomics sub-study SIS-ICF pg 5 be updated to provide a sentence outlining the processing of data such as "I agree for my genomic data to be processed and shared as described in this information sheet" or similar.
- The NREC-CT requests that the GP Letter is updated to include information around risks, side effects and any contraindications of prescribing medications.

2023-504923-20-00

Principal Investigators & Institutions: Tallaght University Hospital (Dr Sebastian Trainor)

Study title: Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

EudraCT: 2023-504923-20-00

- **NREC-CT comments:**
- The NREC-CT A agreed that additional information was required to inform its deliberations before a final ethics position could be returned. RFI

- **NREC-CT Decision:**
- Request for more information

Part I Considerations (RFI) for addition to CTIS
1. No considerations raised
•

Part II Considerations (RFI) for addition to CTIS

1. **Compliance with national requirements on data protection**

- The NREC-CT notes that pg 7 of the _Compliance with National Data Protection specifies data will be retained for +35 years, however the Protocol pg 134 and Main Consent pg 16 states that data will be stored for 25 years. The Committee requests that the Compliance with National Data Protection be updated to align with the information in the Protocol and Main Consent.

2. **Subject information and informed consent form**

- The NREC-CT requests that the Optional Greenphire adult PIS Section 4 p2 be updated to provide more detail on the specific additional personal information that will be shared.
- The NREC-CT requests that the Main Consent PIS be updated to refer to optional consent for Greenphire and that a separate PIS will be signed if participants wish to avail of this service.
- The NREC-CT requests that the Main Consent PIS pg 6 be updated to provide information on how long the questionnaire will take to complete and how frequently they will need to be completed.
- The NREC-CT states that the advice regarding male contraception on pg 13 Main Consent PIS referring to “may not have to take birth control during the trial” would not appear relevant for a male participant. The Committee requests that this is updated to provide more specific advice for male participants.
- The NREC-CT notes the Main Consent PIS pg 13 states that in the event of a female participant becoming pregnant during the trial, data will be collected “about your pregnancy and your baby” however no separate PISCF has been supplied for this. Furthermore, the NREC-CT requests clarification regarding the data that will be collected if a female partner of a male participant becomes pregnant and how will the participant and female partner consent to this. Please provide PISCF as appropriate.
- The NREC-CT notes the first paragraph section 17 pg 13 of Main Consent PIS appears to be guidance to the investigator rather than information for the participant. The Committee requests that this is removed or rephrased such that it is accessible to the participant. .
- The NREC-CT requests that the GP letter and Participant ID card be provided for review.

2023-507881-19-00

Principal Investigators & Institutions: St Vincent’s University Hospital (Dr Eoin Feeney), Beaumont Hospital (Dr Eoghan de Barra), Cork University Hospital (Dr Corinna Sadlier), University Hospital Galway (Dr Geraldine Moloney), St James’s

Hospital (Dr Fiona Lyons), Mater Misericordiae University Hospital (Dr Aoife Cotter)

Study title: Vaccination to prevent Mpox Infection: A Low Intervention Study

EudraCT: 2023-507881-19-00

- **NREC-CT comments:**
- The NREC-CT A agreed that additional information was required to inform its deliberations before a final ethics position could be returned. RFI

- **NREC-CT Decision:**
- Request for more information

Part I Considerations (RFI) for addition to CTIS

1. No considerations raised
-

Part II Considerations (RFI) for addition to CTIS

1. **Financial arrangements**

- The NREC-CT noted that participants will not be compensated for expenses and requested that to ensure access to trials across all socioeconomic groups that participants are reimbursed for out-of-pocket expenses including travel and meal / refreshments and this is detailed in the P1_Compensation trial participants, investigator, funding and other arrangements document.

2. **Subject information and informed consent form**

- It was not clear to the NREC-CT from the study documentation why testing for STDs is required in this research study. Please update the PIL to clarify such that it is clear to participants.
- Furthermore, the NREC-CT requested clarification is provided in the PIL regarding the process which is followed if a person tests positive for STD, and the information provided to the participant.
- The NREC-CT notes that while the PIL does provide a description of physical risks, the potential psychological risks which may be experienced related to testing for STDs is not addressed. The Committee requests that the PIL be updated to reference any potential psychological risks.
- The NREC-CT requests that the PIL be updated to provide information regarding how long each study visit will last.

- The NREC-CT notes that the PIL pg 7 states that personal data will only be shared with named co-investigators listed. The NREC-CT requested clarification as to whether data will also be shared with other members of their research team at each site ,and if so, in what format it will be shared i.e., identifiable or pseudonymised. If information is to be shared with other members of the research team, this should be stated in the PIL.
- The NREC-CT notes that PIL section 5.2 pg 8 lists third parties with whom data may be shared to include relevant industry bodies, they also note that there is a statement that this is done in accordance with Data Protection Legislation. It was unclear to the Committee what the legislative grounds for sharing this information with industry bodies was. Please update the PIL to clarify.
- The NREC-CT requests that the PIL Section 8 pg 9 be reordered to list the rights of the participant first and then subsequently list the rights that may be restricted.
- The NREC-CT notes the statement regarding Collection Storage and future use of biological samples states that samples will be stored for future use. However the PIL does not contain any reference to future use of samples. The Committee requests that if future use of samples is intended, the PIL be updated to include reference to the storage and future use of samples including what purpose the future use may be and that ethics approval with be sought for all future research studies using these samples. Please also update the consent page to include a separate statement around the storage and future use of samples for participants to be able to provide explicit consent for this.
- The NREC-CT states that reference to legal representative pg 12 and 13 in the PIL is misleading as only adults with decision making capacity can consent to take part in this trial. The Committee requests that the PIL be updated to remove reference to legal representative.
- The NREC-CT noted that participants will not be compensated for expenses and requested that to ensure access to trials across all socioeconomic groups that participants are reimbursed for out-of-pocket expenses including travel and meal / refreshments and this is elucidated in the PISCF. The NREC-CT also requested that the process for claiming expenses is clearly explained in the PISCF.

3. Suitability of the clinical trial sites facilities

- The NREC-CT requests a completed Site Suitability form for St Vincent's University Hospital and University Hospital Galway.

4. Suitability of the investigator

- The NREC-CT requests that a Declaration of Interest be submitted for Dr Geraldine Moloney, University Hospital Galway.

23-NREC-CT-039_Mod-2

Principal Investigators: Dr Cormac Owens

Study title: FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

EudraCT: 2018-000515-24

- **NREC-CT comments:**
- The NREC-CT A agreed that additional information was required to inform its deliberations before a final ethics position could be returned. RFI

- **NREC-CT Decision:**
- Request for more information

Aged 16+ study entry PIS

- The NREC-CT requests that p.10, Contacts for further Information be updated to delete reference to “your child”, as this PIS is directed at Participants, and not Parent/Guardians.
- The NREC-CT requests correction of a typo on pg 4 “remiainingr”
- The NREC-CT notes that on pg 5 Genetic Tests it states that “You will not be notified of any results”. The Committee requested clarification as to whether patients can request the results.
- The NREC-CT notes that pg 8 states that “The scans are anonymised as far as possible before they are uploaded to the database but may contain some information about you such as name, date of birth and hospital number” The Committee were unclear why participants names, date of births and hospital numbers would need to be listed on the scans, please clarify.
- The NREC-CT requests that pg10 be updated to state that HPRA also reviewed the trial.

Aged 16+ Relapse randomisation PIS

- The NREC-CT requests that the PIS be updated to provide greater clarity on what is meant by common and rare in relation to side effects of individual drugs.
- The NREC-CT noted a typo on pg 11 where the word ‘*not’* is missing from “You will receive any money.

Aged 13-15 Years CT3 PIS

- The NREC-CT queried whether there is a typo on pg4 in the term '*ECG Pregnancy test'*
- The NREC-CT requests that the PIS be updated to provide greater clarity on what is meant by common and rare in relation to side effects of individual drugs.

Parent Guardian Study entry PIS

- The NREC-CT requests that the PIS be updated to provide greater clarity on what is meant by common and rare in relation to side effects of individual drugs.

Parent/Guardian CT3 PIS

- The NREC-CT requests that the PIS be updated to provide greater clarity on what is meant by common and rare in relation to side effects of individual drugs.

- **Additional Information**
- None

22-NREC-CT-170_Mod-1

Principal Investigators & Institutions: Prof. Owen Smith

Study title: ALLTogether1 – A Treatment study protocol of the Altogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

EudraCT: 2018-001795-38

- **NREC-CT comments:**
- The NREC-CT A agreed that additional information was required to inform its deliberations before a final ethics position could be returned.

- **NREC-CT Decision:**
- Request for more information

- **Additional Information**
- The NREC-CT requests that that Biobanking ICF be submitted for review and approval.

- The NREC-CT notes that the product characteristics on Prednisolone advises not availing of vaccines while on therapy however this is not stated in PILCF for Down Syndrome participants who are a vulnerable group. The Committee requests that the Non-Randomised Intervention 2 (NR12) ALLTogether1 DS PISs are updated to include this advice.

- The NREC-CT requested confirmation is provided as to whether this substantial amendment has received HPRA approval to date.

- The NREC-CT requests that the DS PISCF's be updated throughout to refer to participant/young adult /child and not solely child as the research study involves participants up to the age of 45.

- AOB:

None